Korea Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae Cho, discusses the importance of creating a test tailored to Asian patients, explores the company’s expansion plans into China, Japan, and Southeast Asia, and the synergies in their partnerships with big…
Korea Yeul-Hong Kim, Director of K-MASTER details the project’s success in creating a shared database of genomic data for Korean oncology professionals. Kim also explains the importance of collaboration with Big Pharma in their oncology projects, and the potential to become a pan-Asian venture in the future. It is very…
Hong Kong Alex Wong, CEO of Xcelom sat down with PharmaBoardroom to discuss the company’s non-invasive prenatal testing (NIPT) technology and increasing capacity in the field of screening for chromosomal disorders. Wong sheds light on the Asian diagnostics market and unveils his strategy to expand Xcelom’s offering across Asia. Our pursuit…
Korea Genome & Company, with a market cap of USD 280 million, is the highest valued microbiome company worldwide. Dr Jisoo Pae, its co-founder and CEO, sat down with PharmaBoardroom to shed light on the company’s origins, its collaboration with Big Pharma, and the ease of gaining capital investment for a…
Taiwan Johnsee Lee and Eric Yang of Taiwanese precision medicine diagnostics firm Quark Biosciences outline their technology’s unique characteristics, how it differs from sequencing technologies in terms of cost and speed, and their strategy for the Asia-Pacific region and beyond. Our solution is akin to capsule coffee. One machine can…
Hungary István Peták, co-founder and CEO of Oncompass introduces the innovative start-up and elaborates on how its solution for digital treatment planning and digital biomarkers can revolutionize not only personalized oncology treatment for patients, but also be a key tool in accelerating the clinical development of new targeted therapies. The…
Pharma Faces Paolo Carli, head of Middle East, Africa, Turkey, Russia and CIS (MEAR) for Merck has continually taken on greater responsibilities in the Middle East, Africa, Turkey and Eastern Europe. In his most recent interview with PharmaBoardroom, Carli talks strategy, adaptability, and sales growth. We look at structuring markets with…
China Li Qing of Illumina China discusses his recent move to the company, the strategic significance of the China market to Illumina global, and the competitive landscape for next generation sequencing (NGS) in China. 2018 was a milestone year for Illumina China because we received NMPA approval of our diagnostic…
Taiwan Mengchu Wu, CEO of Health Genetech, introduces the innovative precision medicine company as it prepares to transition from a research-positioned provider to a healthcare partner. Wu goes on to offer her insights on the key market trends impacting the emerging field of precision medicine and shares her outlook on the…
Taiwan Dr Jeffery Tzen, president of the Taiwanese Society of Molecular Medicine and precision medicine key opinion leader, offers insights into Taiwan’s adoption of the emerging field. In order to succeed in translating precision medicine to clinical practice, quality laboratories under strong regulations must be created What motivates you…
Taiwan Eric Yang, secretary general of the Taiwan Precision Medical and Molecular Diagnostics Industry Association (PMMD), speaks about the key challenges facing the sector and the top priorities of the organization and its member companies. Yang goes on to share his insights on the opportunities that exist for precision medicine and…
Sweden Amy Van Buskirk, general manager of Roche Sweden, discusses the role Roche plays in the Swedish healthcare system, how Sweden is becoming an innovation leader once more as well as a frontrunner in precision medicine, and explains how Roche wants to build strategic partnerships and form lasting relationships in order…
See our Cookie Privacy Policy Here